Novelion Therapeutics appoints board member

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
In PersonPolitics & Policy: Market Impacts and Mid-Year Outlooks
- 06/24/2022
- Sofitel Washington DC Lafayette Square
- 8:30 AM – 12:00 PM ET
Webinar ReplaysExpand Your Perspective: Analyzing Deal Activity & Drivers Across the Capital Markets
- 06/08/2022
- On-Demand
- 1 Hour
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
- ARIA Resort and Casino
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

In This List

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

31 Mar, 2017 | 11:53

Author Ira Regmi
Theme Healthcare & Pharmaceuticals

Novelion Therapeutics Inc. appointed Mark Corrigan to its board of directors.

Corrigan is the former CEO and president of Zalicus Inc. He currently serves on the board of Cardiome Pharma Corp. and on the supervisory board of Nabriva Therapeutics AG.